An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland
Richard F Pollock,1 Lisa M Meckley2 1Ossian Health Economics and Communications GmbH, Health Economics and Outcomes Research, Basel, Switzerland; 2Shire Plc, Outcomes Research and Epidemiology, Cambridge, MA, USA Introduction: While most individual primary immunodeficiency diseases (PID) are rare, t...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Llibre |
| Publicat: |
Dove Medical Press,
2018-04-01T00:00:00Z.
|
| Matèries: | |
| Accés en línia: | Connect to this object online. |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Còpia 1 | Disponible |